The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCTI.L Regulatory News (CTI)

  • There is currently no data for CTI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

19 May 2010 15:32

RNS Number : 2180M
Cathay International Holdings Ld
19 May 2010
 



 

19 May 2010

 

Cathay International Holdings Limited

Interim Management Statement

 

Cathay International Holdings Limited (the "Company") announces its Interim Management Statement for the period from 1 January 2010 to 14 May 2010:

 

Highlights of the period

 

·; On 21 January 2010, the Company announced, inter alia, the appointment of Mr. Lee Jin Yi as an executive director and Chief Executive Officer of the Company and the appointment of Mr Eric Siu as Finance Director of the Company.

 

·; On 12 February 2010, the Company announced further investments in Xian Haotian Bio-Engineering Technology Co. Limited ("Xian Haotian") and its subsidiaries and related companies (the "Xian Haotian Group").

 

·; On 1 April 2010, the Company announced the flotation of Lansen Pharmaceutical Holdings Company Limited ("Lansen"), a subsidiary of the Company, on the Hong Kong Stock Exchange, and the associated partial disposal of Lansen.

 

·; On 27 April 2010, the Company announced the preliminary annual results of the Group for the year ended 31 December 2009.

 

·; On 6 May 2010, the Company announced the successful closing of the placing and public offer of shares in Lansen.

 

Further investments in the Xian Haotian Group

 

On 12 February 2010, the Company announced further investments in the Xian Haotian Group, following which Xian Haotian is now an indirectly wholly owned subsidiary of the Company. The investment made in the Xian Haotian Group during the period was approximately US$13 million, which brings the total investment made to date to approximately US$33 million.

The Xian Haotian Group is one of the Company's major investments in the healthcare and pharmaceutical sector in China. Going forward, inositol will be the core product of the Xian Haotian Group, and the Company anticipates that the inositol business will become a major contributor to the growth in the Group's profits in 2011 and beyond. The inositol project is expected to commence production in the second half of 2010.

 

Flotation and Partial Disposal of Lansen

 

As announced on 6 May 2010, the public offer of shares in Lansen was approximately 852 times oversubscribed and the flotation offer price was set at HK$3.91 per share. The net proceeds of the flotation payable to Lansen, after deducting fees and expenses, were approximately HK$350.4 million (US$45.1 million). The net proceeds of the partial disposal received by the Company were approximately HK$114.9 million (US$14.8 million). Dealings in Lansen's shares on the Hong Kong Stock Exchange commenced on 7 May 2010.

 

Following completion of the flotation and the partial disposal, the Company indirectly holds approximately 52.46% of Lansen. Assuming that the over-allocation option provided under the terms of the flotation is exercised in full, the Company will indirectly hold approximately 50.56% of Lansen.

 

The effect of the flotation and partial disposal on the financial position of the Group has been an increase in net assets.

 

The financial performance of the Group in the period since the 2009 year end have been in line with the Company's expectations, and the outlook for the full year remains unchanged that expressed in our preliminary announcement of results on 27 April 2010.

 

Except for the further investment in the Xian Haotian Group and the net proceeds received from the flotation and partial disposal of Lansen, there has been no significant change to the financial position of the Group since that reported as at 31 December 2009.

 

 

For further information, please contact:

 

Eric Siu (Finance Director)

Patrick Sung (Director and Controller)

(via Brunswick)

020 7404 5959

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSZKLFFBEFLBBK
Date   Source Headline
1st Apr 20118:59 amRNSGrant of Share Options
24th Mar 20119:02 amRNSAnnual Report and Accounts
18th Mar 20119:09 amRNSGrant of share options
16th Mar 20117:00 amRNSAnnual Results for the Year Ended 31 December 2010
10th Mar 20119:55 amRNSNotice of Results
9th Mar 20117:00 amRNSAppointment of Adviser
29th Nov 20107:30 amRNSZhejiang Starry Pharmaceutical Co., Ltd.
19th Nov 20107:27 amRNSInterim Management Statement
16th Nov 20107:00 amRNSZhejiang Starry Pharmaceutical Co., Ltd.
26th Aug 20105:04 pmRNSINTERIM RESULTS 2010
4th Jun 20107:00 amRNSResults of AGM and change of Director's role
1st Jun 20107:06 amRNSLansen Pharmaceutical Holdings - Update
19th May 20103:32 pmRNSInterim Management Statement
12th May 201010:37 amRNSAnnual Information Update
6th May 20107:32 amRNSLansen Pharmaceutical Holdings Company Limited
27th Apr 20104:25 pmRNSLansen Pharmaceutical Holdings Company Limited
27th Apr 20104:22 pmRNSPRELIMINARY RESULTS
19th Apr 20101:41 pmRNSResult of Special General Meeting
16th Apr 201012:38 pmRNSSpecial General Meeting on 19 April 2010
6th Apr 20105:18 pmRNSPublication of Circular
1st Apr 20101:09 pmRNSLansen Pharmaceutical Holdings Company
23rd Mar 20109:00 amRNSAdditional Listing
26th Feb 20109:07 amRNSAdditional Listing
12th Feb 20106:06 pmRNSUpdate on further investment in Xian Haotian Group
26th Jan 20105:18 pmRNSAnnual Information Update
21st Jan 20105:56 pmRNSAppointment of Directors and Issue of Equity
7th Dec 20099:11 amRNSTotal Voting Rights and Share Capital
4th Dec 200911:16 amRNSResult of SGM
4th Dec 20097:06 amRNSResult of Placing Open Offer
19th Nov 200911:03 amRNSInterim Management Statement
18th Nov 20095:24 pmRNSPublication of Prospectus
18th Nov 20097:00 amRNSPlacing and Open Offer
26th Aug 20092:00 pmRNSInterim Results 2009
22nd Jul 20094:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20094:35 pmRNSPrice Monitoring Extension
26th May 200911:08 amRNSHolding(s) in Company
1st May 20099:30 amRNSDirectorate Change
1st May 20099:28 amRNSResult of AGM
1st May 20097:00 amRNSDIRECTORATE CHANGE
14th Apr 20091:45 pmRNSInterim Management Statement
6th Apr 20095:30 pmRNSPRELIMINARY RESULTS
23rd Jan 200912:27 pmRNSAnnual Information Update
19th Nov 200811:04 amRNSInterim Management Statement
12th Sep 20082:09 pmRNSFurther Update on Xian Haotian
29th Aug 20084:00 pmRNSInterim Results
30th May 20083:18 pmRNSResult of AGM and SGM
19th May 20087:30 amRNSInterim Management Statement
29th Apr 20082:47 pmRNSFinal Results
29th Apr 20088:39 amRNSXian Haotian Circular
28th Apr 20082:09 pmRNSCirc re Xian Haotian

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.